



U.S. Food and Drug Administration
Division of Pharmaceutical Quality Operations III
300 River Place, Suite 5900
Detroit, MI 48207
Telephone: (313) 393-8100
Fax: (313) 393-8139
www.fda.gov

February 21, 2018

UPS NEXT DAY

Robert Kulak, R.Ph.
Director of Pharmacy
PharMerica, LLC
6330 E 75th Street Suite 322
Indianapolis, Indiana 46250

Dear Mr. Kulak:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, PharMerica, LLC, located at 6330 E 75th Street Suite 322 Indianapolis, IN 46250-2708, from February 6, 2017, to February 23, 2017, by the U.S. Food and Drug Administration (FDA). In addition, we are enclosing the letter sent to the Indiana State Board of Pharmacy for follow up.

When the Agency considers an inspection to be “closed” under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment and we have enclosed a copy with this letter.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please contact Tina M. Pawlowski, Ph.D., Compliance Officer, at (313-393-8217) or by email at: ORAPHARM3_RESPONSES@fda.hhs.gov.

Sincerely,

Nicholas F. Lyons

-S

Nicholas F. Lyons
Compliance Director
Division of Pharmaceutical Quality Operations III

Digitally signed by Nicholas F. Lyons -S
DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People,
0.9.2342.19200300.100.1.1=1300120033, cn=Nicholas F. Lyons -S
Date: 2018.02.21 10:52:41 -06'00'

Enclosures: EIR and State Referral Letter